Gastroenterology Research and Practice

Research Article

Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern Italy

Table 1

Demographic and clinical characteristics. Data are crude numbers (percentages) or median (min-max). UC: ulcerative colitis; CD: Crohn’s disease; 5-ASA: mesalazine; steroids (topical and/or systemic); IMM: immunomodulators (azathioprine, 6-mercaptoruine, and methotrexate); biologics: anti-TNFα (infliximab and adalimumab).
Number of patients included509
Gender, M/F300/209
Age, median (range), years42 (17–87)
Disease, CD/UC289 (56.8%)/220 (43.2%)
 (i) CD: M/F179/110
 (ii) CD: age, median (range), years42 (17–81)
 (iii) CD (Montreal classification) 
   L1152 (52.6%)
   L239 (13.5%)
   L398 (33.9%)
   L48 (2.8%)
 (i) UC: M/F121/99
 (ii) UC: age, median (range), years42 (17–87)
 (iii) UC (Montreal classification) 
   E119 (8.6%)
   E2111 (50.5%)
   E390 (40.9%)
Duration of disease, median (range), months 
 (i) Total population56 (0–612)
 (ii) CD60 (0–612)
 (iii) UC48 (0–600)
Drug treatment (before screening) 
 (i) 5-ASA (%) (total/CD/UC)465 (91.4%)/258 (89.3%)/207 (94.1%)
 (ii) Steroids (%) (total/CD/UC)439 (86.2%)/244 (84.4%)/195 (88.6%)
 (iii) IMM (%) (total/CD/UC)174 (34.2%)/106 (36.7%)/68 (30.9%)
 (iv) Biologics (%) (total/CD/UC)80 (15.7%)/54 (18.7)/26 (11.8%)